Walker-Warburg syndrome (WWS) is clinically defined as congenital muscular dystrophy that is accompanied by a variety of brain and eye malformations. It represents the most severe clinical phenotype in a spectrum of diseases associated with abnormal post-translational processing of a-dystroglycan that share a defect in laminin-binding glycan synthesis 1 . Although mutations in six genes have been identified as causes of WWS, only half of all individuals with the disease can currently be diagnosed on this basis 2 . A cell fusion complementation assay in fibroblasts from undiagnosed individuals with WWS was used to identify five new complementation groups. Further evaluation of one group by linkage analysis and targeted sequencing identified recessive mutations in the ISPD gene (encoding isoprenoid synthase domain containing). The pathogenicity of the identified ISPD mutations was shown by complementation of fibroblasts with wild-type ISPD. Finally, we show that recessive mutations in ISPD abolish the initial step in laminin-binding glycan synthesis by disrupting dystroglycan O-mannosylation. This establishes a new mechanism for WWS pathophysiology.
Walker-Warburg syndrome (WWS) is clinically defined as congenital muscular dystrophy that is accompanied by a variety of brain and eye malformations. It represents the most severe clinical phenotype in a spectrum of diseases associated with abnormal post-translational processing of a-dystroglycan that share a defect in laminin-binding glycan synthesis 1 
. Although mutations in six genes have been identified as causes of WWS, only half of all individuals with the disease can currently be diagnosed on this basis 2 . A cell fusion complementation assay in fibroblasts from undiagnosed individuals with WWS was used to identify five new complementation groups. Further evaluation of one group by linkage analysis and targeted sequencing identified recessive mutations in the ISPD gene (encoding isoprenoid synthase domain containing). The pathogenicity of the identified ISPD mutations was shown by complementation of fibroblasts with wild-type ISPD. Finally, we show that recessive mutations in ISPD abolish the initial step in laminin-binding glycan synthesis by disrupting dystroglycan O-mannosylation. This establishes a new mechanism for WWS pathophysiology.
The hallmark of dystroglycanopathies-and the common pathogenic denominator in all individuals with WWS (MIM 236670)-is loss of functional glycosylation of α-dystroglycan 3 . Lack of proper α-dystroglycan glycosylation reduces binding to extracellular matrix proteins, as ligand binding is mediated through the sugar moiety on α-dystroglycan 3, 4 . All six of the genes in which causative mutations in WWS have previously been found code for known or putative glycosyltransferases; mutations in these genes show autosomal recessive inheritance patterns and result in abnormal α-dystroglycan glycosylation 5 . Nevertheless, approximately half of the population with WWS has no mutation in these known genes 2 , emphasizing the need for discovery of other causative genes that are disrupted in WWS.
We established a complementation assay to enable us to identify additional genes that contribute to WWS pathology. This assay was developed based on a panel of skin fibroblasts derived from six individuals with genetically defined but heterogeneous dystroglycanopathy ( Supplementary Table 1 ), in which protein blotting revealed a lack of functional glycosylation (defined as immunoreactivity to IIH6, a monoclonal antibody specific for the requisite sugar moiety) and an inability to bind laminin (Fig. 1a) . These pathological characteristics are consistent with previously published data obtained from various dystroglycanopathy tissues 3, 6 and cells [7] [8] [9] . Notably, the degree of α-dystroglycan hypoglycosylation varied with the gene mutated, and the differing molecular weights of α-dystroglycan produced in the individual fibroblast populations are hypothesized to reflect abnormalities at different steps in α-dystroglycan biosynthesis (Fig. 1a) . In fibroblasts from each population of affected individuals, the α-dystroglycan glycosylation defect was rescued by introducing a wild-type copy of the mutant gene. For example, in fibroblasts from individuals with WWS with known POMT1 mutations, α-dystroglycan functional glycosylation was restored by adenovirus-mediated gene transfer of POMT1 but not by expression of the other known WWS-associated genes (Fig. 1b) . This complementation assay was adapted to On-Cell protein blotting technology, and rescue of α-dystroglycan functional glycosylation was shown for all known WWS-associated genes (Fig. 1c) .
ISPD loss-of-function mutations disrupt dystroglycan O-mannosylation and cause Walker-Warburg syndrome l e t t e r s Previously, it was shown that forced overexpression of the glycosyltransferase LARGE induces α-dystroglycan hyperglycosylation in control cells and bypasses the α-dystroglycan glycosylation defect in cells from individuals with dystroglycanopathy 8, 10 . However, we now show that the ability of LARGE to hyperglycosylate α-dystroglycan is dependent on the availability of O-mannosyl phosphate acceptor sites and correlates with the severity of the clinical phenotype (Fig. 1d) .
We next applied the On-Cell complementation assay to fibroblasts derived from a cohort of 63 individuals with dystroglycanopathy ( Supplementary Fig. 1 ), identifying 11 subjects with WWS in 10 unrelated families who we postulated to have mutations in genes not previously implicated in WWS. Our first step toward defining the genetic basis for WWS in these individuals was to establish complementation groups; to this end, we adapted a cell fusion approach that is commonly used in yeast 11 and that has also proven successful in mammalian cells 12 . Whereas fusion is achieved by mating in the case of yeast cells, polyethylene glycol (PEG) 13 treatment is used to induce fusion in mammalian cells. We hypothesized that fusion between co-cultured cells from affected individuals harboring recessive mutations in the same gene would not rescue the α-dystroglycan glycosylation defect, whereas fusion between cells from affected individuals with independent genetic defects would result in successful rescue. Immunofluorescence analysis identified IIH6-positive fused cells (as indicated by the presence of multiple nuclei) only when two cell lines from genetically different individuals were co-cultured; for example, complementation between POMT1-and FKTN-deficient fibroblasts from subjects with WWS is shown ( Fig. 2a) . Two-way fusions of WWS-derived cells with mutations in each of the known genes rescued α-dystroglycan glycosylation (data not shown). Application of the npg l e t t e r s PEG fusion approach to all 11 subjects with WWS for whom a genetic cause had not been determined led to the identification of five separate complementation groups (Fig. 2b,c ), suggesting that five new causative genes in WWS were represented in this small cohort. Four complementation groups were represented by a single subject with WWS, and one complementation group consisted of seven subjects with WWS. If mutations in a single newly implicated gene are responsible for disease in all seven subjects, then the genetic alterations in this complementation group likely represent a relatively common cause of WWS.
All seven subjects within this complementation group met the classic diagnostic criteria for WWS (Supplementary Table 2 ). Two of the subjects, P5 (refs. 6, 14) and P6 (ref. 15), were described as having WWS in previously published studies. In the case of P1, brain magnetic resonance imaging (MRI) performed at 3 days and at 5 months of age showed hydrocephalus, cobblestone lissencephaly of the cerebral cortex, severe brainstem hypoplasia with a kink at the isthmus and severe hypoplasia of the cerebellum (Fig. 3a) . This subject also showed evidence of severe muscular dystrophy ( Fig. 3b) , bilateral microphthalmia with cataracts and arrested retinal development. Immunofluorescence and protein blot analysis of a skeletal muscle from this subject showed that individuals in the new WWS complementation group manifested the typical α-dystroglycan glycosylation defect in skeletal muscle, with loss of both functional glycosylation and receptor function (Fig. 3b,c) . Comparative analysis of the status of α-dystroglycan glycosylation in fibroblasts from five different subjects within this same WWS complementation group confirmed that all shared a defect in α-dystroglycan processing, showing complete loss of functional glycosylation and laminin binding ( Supplementary Fig. 2) . Moreover, the loss of post-translational modification of α-dystroglycan and its consequent shift to a lower molecular weight were comparable in all samples, consistent with the hypothesis that individuals from this complementation group share a common genetic defect.
Our first step toward identifying the underlying genetic defect in the large complementation cohort was to perform linkage analysis. As reliable family history regarding consanguinity was not available for all subjects, regions of homozygosity by descent were identified using high-resolution SNP arrays. Besides the sibling pair of subjects P2 and P3, four of the five unrelated subjects showed multiple long (>10 cM) stretches of homozygosity, suggesting some degree of consanguinity ( Supplementary Fig. 3 ). We searched for chromosomal regions where P2 and P3 were identical on both alleles and where all or a subset of the four suspected consanguineous subjects were homozygous. All 7,113 coding exons across the 14 identified overlapping intervals were subjected to targeted sequencing (Supplementary Table 3 ). All seven samples were barcoded, pooled, captured by a custom-designed capture array and sequenced on a lane of an Illumina HiSeq2000 flow cell as npg l e t t e r s a 50-bp paired-end run. Sequence data were processed in a custombuilt analysis pipeline, and, after variant filtering was applied, six genes were identified in which at least two independent proteindamaging variants passed hard-filtration criteria ( Supplementary  Table 4 ). On the basis of genetic evidence, ISPD was determined to be the most likely candidate gene. After manually examining variants that did not meet filtration criteria and augmenting the data set with Sanger sequencing results for P5, for whom there was poor coverage, a total of four heterozygous and four homozygous variants were found in ISPD that occurred as multiple rare variants in all six independent affected individuals ( Table 1 and Supplementary Fig. 4) . All mutations were predicted to damage or abolish protein function, as expected in individuals with a severe form of dystroglycanopathy, such as WWS 7 . In addition, ISPD is localized to chromosome 7p21.2, a region in which three of the four suspected consanguineous subjects had intervals of homozygosity longer than 10 cM and where P2 and l e t t e r s P3 shared both parental alleles (Fig. 4a,b) . A schematic of all ISPD mutations identified in our subject cohort is shown (Fig. 4c) .
To confirm the pathogenicity of the identified ISPD mutations, we conducted complementation assays on fibroblasts derived from the subjects with WWS who had ISPD mutations. In the subject-derived cells, expression of wild-type ISPD but not that of a mutant isoform (ISPD lacking exon 3 from P6) restored functional glycosylation (Fig. 4d) ; in control cells, this overexpression did not substantially alter functional α-dystroglycan glycosylation (Fig. 4e) . Functional rescue of cells from affected individuals confirmed that the identified ISPD mutations have pathogenic relevance and indicated that severe mutations in ISPD can cause WWS.
Notably, ISPD has not been characterized in mammals. Quantitative RT-PCR (qRT-PCR) revealed that ISPD was ubiquitously expressed in all tissues analyzed, with the highest expression occurring in brain (Supplementary Fig. 5) . The ISPD protein belongs to the family of 4-diphosphocytidyl-2C-methyl-D-erythritol (CDP-ME) synthases (also known as 2-C-methyl-D-erythritol 4-phosphate cytidylyltransferases) that are conserved from bacteria to mammals (Supplementary Fig. 6) .
In Escherichia coli, IspD activity contributes to the methylerythritol phosphate (MEP) pathway in the synthesis of isoprenoid precursors 16, 17 , which give rise to the polyisoprenoid alcohols (for example, dolichols and polyprenols) found in all living organisms 18 (Supplementary Fig. 7) . However, the MEP pathway is used only by eubacteria, green algae and the chloroplasts of higher plants 19 . Eukaryotes, archaebacteria and the cytosol of higher plants are thought to use an alternative, ISPD-independent mevalonate (MVA) pathway for isoprenoid synthesis 20 . As the MEP pathway involving ISPD is postulated to be absent from animals, the specific role of ISPD in humans, especially in regard to α-dystroglycan glycosylation, is unclear.
To investigate the role of ISPD in α-dystroglycan glycosylation, we tested subjects with WWS who had mutations in ISPD for changes in any known step in laminin-binding glycan synthesis. Notably, protein O-mannosylation, the initiating step of this pathway, was markedly reduced in fibroblasts lacking functional ISPD, as were downstream events like O-mannosyl phosphorylation and LARGE-induced hyperglycosylation ( Fig. 5a-c) . These findings suggest that ISPD function is crucial for efficient POMT-dependent O-mannosylation and subsequent glycosylation of α-dystroglycan (Supplementary Fig. 8) .
In this study, we have identified a new disease-associated gene in individuals with WWS by using a fibroblast complementation assay in combination with targeted sequencing. This approach provided conclusive genetic and biochemical evidence that recessive mutations in ISPD lead to impaired α-dystroglycan O-mannosylation, establishing a new pathway and mechanism for disease in WWS. Further studies are needed to determine how mutations in ISPD influence protein O-mannosylation, as this is the first WWS-associated gene without proposed glycosyltransferase activity and a direct role in α-dystroglycan glycosylation.
URLs. UCLA Clinical Genomics Center, http://pathology.ucla. edu/body.cfm?id=105; NINDS DNA and Cell Line Repository, http:// ccr.coriell.org/ninds; Novocraft Short Read Alignment package, http://www.novocraft.com/index.html; SAMtools, http://samtools. sourceforge.net/; Picard, http://picard.sourceforge.net/; SeattleSeq Annotation, http://snp.gs.washington.edu/SeattleSeqAnnotation131/; ExonPrimer, http://ihg.gsf.de/ihg/ExonPrimer.html.
MeThOdS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturegenetics/.
Note: Supplementary information is available on the Nature Genetics website.
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We thank the Gene Transfer Vector Core ( Targeted next-generation sequencing. Regions over 10 cM in length where the sibling pair of P2 and P3 showed IBD for both alleles were selected, as were regions that were homozygous for over 2 cM in one or more of the four samples suspected to come from consanguineous individuals (P4, P5, P6 and P7), and were used to create a custom capture array. Using Agilent eArray, a 244K comparative genomic hybridization (CGH) array was designed to target in total 7,113 coding exons across 14 overlapping intervals ( Supplementary  Table 3 ). Repeat regions were excluded. Genomic DNA (3 µg) was used to generate each sequencing library, using the Agilent SureSelect Target Enrichment System for Illumina Paired-End Sequencing Library Protocol (version 2.0.1); the only difference was that seven different custom-made, barcoded adaptors were used in place of the commercially available adaptor (sequences available on request). After amplification, samples were pooled at equal molar concentrations, captured on one array following an in-house protocol 30 and sequenced on the Illumina HiSeq2000 as 50-bp paired-end reads.
Sequence read alignment. Barcodes were removed from sequence reads, and sequences were aligned to the Human reference genome Build 37 (hg19) using Novobarcode and Novoalign from the Novocraft Short Read Alignment Package (see URLs). Data were processed with SAMtools (version 0.1.15, see URLs) 31 , and potential PCR duplicates were removed using Picard (see URLs). The mean coverage achieved within the intended captured region was 35.9× per base, with 82.2% of the targeted base pairs covered at ≥10×. Local realignment was performed using the GATK 32, 33 IndelRealigner tool.
Variant calling. Variants were called using the GATK Unified Genotyper tool simultaneously for all seven samples. Small indels were called with the -glm npg DINDEL option. Variants with a phred-scaled Q score of ≥50.0 were reported as PASSed calls, and those with a Q score of ≥10.0 and <50.0 were reported as Low Qual calls. Using the GATK VariantFiltrationWalker tool, both SNPs and indels were hard filtered to eliminate low-quality variants. The following filtering parameters were used, which were suggested to be standard by GATK, to remove likely false positive variants: (i) clusterWindowSize of 10, (ii) mapping quality of zero (MAPQ0) of >40, (iii) quality-by-depth (QD) of <5.0 and (iv) strand bias (SB) >−0.10. The GATK VariantEval tool was used to collect the statistics for the PASSed variants ( Supplementary Table 6a ).
Variant annotation. PASSed variants that were not found in dbSNP132 were annotated using SeattleSeq Annotation version 6.16 (see URLs); single-nucleotide variants (SNVs) and indels were annotated separately. Variants present in the 1000 Genomes Project database (March 2010 release) or dbSNP131, as well as those that resulted in coding synonymous changes or affected sequences outside of a coding region, were removed from further analysis ( Supplementary  Table 6b ). The remaining 84 variants were prioritized on the basis of the frequency of coexistence within the same gene.
Copy-number variant (CNV) detection.
To identify exonic deletions within the ISPD gene, the log R ratio (LRR) of the coverage (Cov), Cov i,j / Cov i,P4 was calculated for each exon i in each sample j using ExomeCNV with subject P4 as a control 31 .
Sanger sequencing. Genomic DNA was extracted from dermal fibroblasts or transformed lymphoblastoid cell lines using standard methods (Qiagen DNeasy Blood & Tissue Kit). Coding regions (ten exons) and exon-intron boundaries of ISPD were amplified using PCR (primers sequences and PCR conditions are available upon request). Primer sets for PCR were designed using the web-based design tool ExonPrimer. After PCR amplification, purified products were evaluated by Sanger sequencing using standard protocols.
